(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 June 2008 (19.06.2008)

PCT

(10) International Publication Number
WO 2008/073670 A2

(51) International Patent Classification:
A61K 31/40 (2006.01) *A61K 31/4409* (2006.01)
A61P 7/02 (2006.01) *A61K 31/4412* (2006.01)
A61K 31/4164 (2006.01) *A61K 31/535* (2006.01)
A61K 31/435 (2006.01)

(21) International Application Number:
PCT/US2007/084887

(22) International Filing Date:
15 November 2007 (15.11.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/873,792 8 December 2006 (08.12.2006) US
60/947,629 2 July 2007 (02.07.2007) US

(71) Applicant *(for all designated States except US)*: **MILLENNIUM PHARMACEUTICALS, INC.** [US/US]; 40 Landsdowne Street, Cambridge, Massachusetts 02139 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **SINHA, Uma** [US/US]; 808 Junipero Serra Boulevard, San Francisco, California 94127 (US). **HOLLENBACH, Stanley J.** [US/US]; 450 Alta Vista Drive, South San Francisco, California 94080 (US). **ABE, Keith** [US/US]; 57 Sable Pointe, Alameda, California 94502 (US).


(74) Agent: **TANNER, Lorna L.**; FOLEY & LARDNER LLP, 975 Page Mill Road, Palo Alto, California 94304-1013 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

(54) **Title:** UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR



(57) **Abstract:** Unit doses of factor Xa inhibitor compounds and methods of using these compounds for inhibiting blood coagulation in a human patient are taught herein. The unit dose of the factor Xa inhibitor compounds disclosed herein required to inhibit coagulation in a primate is lower than the unit dose required to obtain similar levels of coagulation inhibition in other animal models, such as rodents. Also taught are in vitro assays useful in predicting in vivo antithrombotic activity in humans.

WO 2008/073670 A2